
Cleveland BioLabs, Inc. Market Cap | CBLI
As of November 22, 2026 Cleveland BioLabs, Inc. has a market cap of $ 49 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Cleveland BioLabs, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 56.9 M | 35.6 M | 17.7 M | 35.9 M | 18.6 M | 26.8 M | 10.6 M | 30.6 M | 58.7 M | 102 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 102 M | 10.6 M | 39.3 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Exelixis
EXEL
|
11.7 B | $ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
169 M | $ 13.09 | -2.68 % | $ 374 M | ||
|
Cardiff Oncology
CRDF
|
116 M | $ 0.85 | -4.67 % | $ 56.8 M | ||
|
BioNTech SE
BNTX
|
22 B | $ 80.87 | -0.63 % | $ 19.5 B | ||
|
Alkermes plc
ALKS
|
5.13 B | $ 44.89 | -2.79 % | $ 7.39 B | ||
|
ANI Pharmaceuticals
ANIP
|
1.24 B | $ 68.6 | -0.77 % | $ 1.38 B | ||
|
AIM ImmunoTech
AIM
|
1.13 M | $ 0.11 | -7.75 % | $ 178 K | ||
|
AC Immune SA
ACIU
|
287 M | $ 1.98 | -7.28 % | $ 199 M | ||
|
Atara Biotherapeutics
ATRA
|
73.6 M | $ 6.51 | 2.6 % | $ 81.7 M | ||
|
Allogene Therapeutics
ALLO
|
545 M | $ 0.63 | -5.62 % | $ 139 M | ||
|
Altimmune
ALT
|
318 M | $ 1.33 | -6.03 % | $ 117 M | ||
|
AnaptysBio
ANAB
|
1.59 B | $ 46.65 | -1.58 % | $ 1.35 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
13.1 B | $ 252.39 | -1.39 % | $ 15.3 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 7.42 | -2.37 % | $ 203 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
1.86 B | $ 14.7 | -1.28 % | $ 1.98 B | ||
|
Autolus Therapeutics plc
AUTL
|
322 M | $ 0.91 | -6.96 % | $ 242 M | ||
|
Atea Pharmaceuticals
AVIR
|
426 M | $ 3.97 | 0.89 % | $ 324 M | ||
|
Axsome Therapeutics
AXSM
|
8.67 B | $ 129.32 | -4.69 % | $ 6.43 B | ||
|
BridgeBio Pharma
BBIO
|
13.1 B | $ 75.96 | -2.84 % | $ 14.5 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
2.25 B | $ 7.23 | -1.3 % | $ 1.52 B | ||
|
Bicycle Therapeutics plc
BCYC
|
351 M | $ 2.89 | -5.25 % | $ 200 M | ||
|
Benitec Biopharma
BNTC
|
562 M | $ 7.95 | -2.4 % | $ 370 M | ||
|
DiaMedica Therapeutics
DMAC
|
312 M | $ 8.24 | 2.74 % | $ 387 M | ||
|
Insmed Incorporated
INSM
|
31.6 B | $ 141.06 | -2.35 % | $ 28.1 B | ||
|
Iovance Biotherapeutics
IOVA
|
1.35 M | $ 6.9 | -5.61 % | $ 2.47 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
4.64 M | $ 4.64 | 17.17 % | $ 56.6 M | ||
|
InMed Pharmaceuticals
INM
|
5.45 M | $ 15.56 | 13.57 % | $ 64.8 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 12.36 | -9.55 % | $ 799 M | ||
|
Immutep Limited
IMMP
|
2.97 B | $ 3.11 | -9.06 % | $ 4.53 B | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
10.5 B | $ 228.26 | -3.46 % | $ 13.9 B | ||
|
BeyondSpring
BYSI
|
69.1 M | $ 0.33 | -24.42 % | $ 13.6 M | ||
|
Cabaletta Bio
CABA
|
283 M | $ 0.94 | -7.24 % | $ 94.5 M | ||
|
Johnson & Johnson
JNJ
|
379 B | $ 270.2 | 1.18 % | $ 650 B | ||
|
Cue Biopharma
CUE
|
29.4 M | $ 4.2 | -6.67 % | $ 398 M | ||
|
C4 Therapeutics
CCCC
|
234 M | $ 2.49 | 1.84 % | $ 206 M | ||
|
Codexis
CDXS
|
111 M | $ 1.0 | -5.17 % | $ 87.1 M | ||
|
Kamada Ltd.
KMDA
|
490 M | $ 7.75 | -1.02 % | $ 447 M | ||
|
Compugen Ltd.
CGEN
|
196 M | $ 1.83 | -2.66 % | $ 171 M | ||
|
Coherus BioSciences
CHRS
|
226 M | $ 0.37 | -4.06 % | $ 43.3 M | ||
|
Armata Pharmaceuticals
ARMP
|
312 M | $ 3.06 | 2.68 % | $ 111 M | ||
|
Celldex Therapeutics
CLDX
|
2.04 B | $ 27.36 | -2.15 % | $ 1.82 B | ||
|
Cellectis S.A.
CLLS
|
335 M | $ 0.9 | -9.7 % | $ 90.3 M | ||
|
Lineage Cell Therapeutics
LCTX
|
421 M | $ 0.78 | -4.87 % | $ 179 M | ||
|
Edesa Biotech
EDSA
|
11.3 M | $ 2.01 | -7.59 % | $ 11.4 M | ||
|
Eli Lilly and Company
LLY
|
940 B | $ 1 345.4 | -0.44 % | $ 1.21 T | ||
|
Collegium Pharmaceutical
COLL
|
1.4 B | $ 24.73 | -1.9 % | $ 783 M | ||
|
Evogene Ltd.
EVGN
|
6.38 M | $ 0.32 | 1.02 % | $ 2.52 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 2.05 | -15.81 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
335 M | $ 76.99 | 0.03 % | $ 997 M |